Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocertatug Rezetecan in Advanced Solid Tumors
NCT06431594Phase 1Recruiting
- Sponsor
- GSK
- Start
- Jul 2024
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 15
01
Overview
Phase 1, open-label trial of mocertatug rezetecan in solid tumor, ovarian cancer and endometrial cancer (EC) (2 arms), sponsored by GSK. Primary endpoints: Dose Limiting Toxicity at 21 days and Objective Response Rate at 28 months. Started Jul 2024; status: recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
solid tumorovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT06431594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06431594.